Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRZ1J4
|
|||
| Drug Name |
HuMNC2-CAR44 T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1 | [1] | |
| Company |
Minerva Biotechnologies
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04020575) Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Minerva Biotechnologies. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.